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Hepatoblastoma (HB) is the most common pediatric liver malignancy with an annual
incidence of 1.8 cases per million children. The median age at diagnosis is 1-year-old. 
Most cases are sporadic, although certain genetic disorders such as Beckwith-
Wiedemann syndrome and familial adenomatous polyposis are associated with 
increased risk of HB. 
Developmental pathways, such as WNT/β-catenin and Hedgehog signaling, are often 
aberrantly activated in HB cells. The overall mutation burden in HB is generally low, 
but the CTNNB1 gene encoding β-catenin is altered in over 60 % of cases. HB histology 
resembles embryonal or fetal liver. Functions carried out in developing liver, like alpha-
fetoprotein synthesis and extramedullary hematopoiesis, are also characteristic of HB. 
Surgical resection of tumor is a mainstay of HB treatment, generally supported by pre-
and post-operative chemotherapy. Platinum-derivatives and doxorubicin form the
cornerstone of pharmaceutical HB management, though multiorgan toxicity limits the
use of these drugs. The survival rate of HB is over 80 % if tumor is confined to liver but 
decreases dramatically when there is extrahepatic involvement, so new treatment 
options are needed.
In this thesis we examined two key factors, GATA4 and neuropilin-2, in the 
pathobiology of HB. Additionally, we conducted in vitro experiments investigating the
potential of chloroquine as a novel HB therapy. For these analyses, we used patient 
tumor samples and multiple HB cell lines cultured in both two- and three-dimensional 
formats.
Transcription factor GATA4 is crucial for early liver development. We observed that 
most HB patient samples and cell lines express high levels of GATA4. To investigate 
its role in oncogenesis, we silenced GATA4 expression in HUH6 HB cells via small 
interfering RNA (siRNA) transfection. We performed mRNA microarray hybridization 
to identify genes affected by GATA4 knockdown. Genes related to epithelial-
mesenchymal transition (EMT) were dysregulated after GATA4 silencing.
Immunofluorescence staining demonstrated increased E-cadherin expression and 
decreased N-cadherin expression after GATA4 knockdown, suggesting reversed EMT. 
We also observed reduced actin polymerization and lower migration rate in GATA4 
silenced cells, implying that GATA4 promotes a more aggressive mesenchymal 
phenotype in HB cells. 
Neuropilins (NRP) are multifunctional receptors involved both in physiological and 
pathological processes. In cancer cells abundant NRP expression is associated with 
chemoresistance, increased proliferation, and higher metastasis rate. We noted high 
NRP1 and NRP2 expression in HB patient samples and six HB cell models. Utilizing 
siRNA transfection, we observed decreased viability and motility in NRP2 knockdown 
cells compared to HB cells with intact gene expression. Furthermore, actin 
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depolymerization increased and cell protrusions decreased after NRP2 silencing in HB 
cells suggesting that NRP2 expression promotes malignant behavior in HB. 
Chloroquine is a traditional anti-malarial which has demonstrated potential in cancer 
management both in vitro and in vivo. We observed a drastic decrease in HB spheroid 
viability after chloroquine treatment. Moreover, chloroquine triggered increased 
apoptosis in most of the cell culture models studied. Chloroquine treatment also 
modified the metabolic profile of HB cells with a remarkable decrease in NAD+ and 
aspartate concentrations. Death pathway qPCR array demonstrated decreased 
poly(ADP)-ribose polymerase (PARP)1/2 expression after chloroquine treatment, and 
this was confirmed with protein analysis. Taken together, we demonstrated that 
chloroquine has anti-tumorigenic potential in HB cell models and its mechanism of 
action may be linked to altered DNA repair. 
In summary, this thesis shed new light on the molecular mechanisms of HB 
pathogenesis. In the future, these findings may be utilized in development of novel 
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REVIEW OF THE LITERATURE
1 LIVER
1.1 Development
The post-gastrulation embryo is composed of three germ layers: ectoderm, 
mesoderm, and endoderm. Liver develops from endoderm, the innermost germ layer.
The process of hepatogenesis can be divided into three major stages: hepatic 
specification, liver bud formation and growth, and epithelial differentiation (Figure
1) [reviewed in (1)].
Hepatic specification entails establishment of hepatic competence in the ventral 
foregut endoderm resulting in the appearance of hepatoblasts. Forkhead box protein
A (FOXA) (2) and GATA transcription factors (GATA4/6) (3) modify chromatin 
structure to unmask hepatic gene regions enabling their subsequent activation. 
During hepatoblast specification, foregut endoderm closely interacts with septum 
transversum mesenchyme and cardiac mesoderm. Animal studies have shown that 
bone morphogenetic proteins (BMPs) and fibroblast growth factors (FGFs) play 
important roles in inducing gene expression pattern leading to the rise of hepatoblasts 
(4,5).
In the next phase of organogenesis, hepatoblasts invade septum transversum 
mesenchyme forming a liver bud. Thereafter, hepatoblasts proliferate rapidly and the
nascent liver expands under the influence of signals from septum transversum 
mesenchymal cells and neighboring endothelial cells (reviewed in 1). Several
transcription factors have been recognized to take a part to this process, including
GATA4/6, hepatocyte nuclear factor 6 (HNF6), onecut 2 (OC2), prospero-related 
homeobox 1 (Prox1), haematopoietically-expressed homeobox factor (HHEX), and 
T-box transcription factor 3 (Tbx3) [reviewed in (6)].
Shortly after liver bud formation, bipotential hepatoblasts start to differentiate into 
hepatocytes and cholangiocytes. This process commences approximately at
gestation week 9 in humans and continues until the beginning of the last trimester
(7,8). The mechanisms regulating liver epithelial differentiation are not fully 
understood, but HNF1α, HNF4α, and CCAAT/enhancer binding protein-α (9) have 
have significant roles in hepatocyte lineage specification, whereas HNF1α, SRY-












1.2 Gross anatomy  
 
The liver resides in the upper-right quadrant of the abdominal cavity, inferior to the 
diaphragm and superior to the stomach, intestines, and right kidney. The liver is the 
second largest organ in the human body weighting approximately 1400-1800 g in adults 
(12) and 150 g in the newborns (13). The organ is divided into two lobes (right and left) 
separated by falciform ligament, which joins the liver to the anterior abdominal wall. 
Functionally, the liver can be further divided into eight segments (Figure 2) based on 
blood supply and bile drainage (14). The liver receives blood from two sources: 
oxygenated blood comes from the hepatic artery (20 %) and portal vein (80 %) brings 
blood from the intestines. Outflow from the liver is directed to three major hepatic veins 
terminating in the inferior vena cava.  
Biliary anatomy is composed of intrahepatic and extrahepatic parts (15). Intrahepatic 
bile canaliculi drain bile to the hepatic ducts which unite to form the common hepatic 
duct. Outside the liver, the common hepatic duct joins with the cystic duct originating 
from the gallbladder. These two ducts form a common cystic duct draining bile into the 
duodenum.   
 
Figure 1. Simplified view of the liver development from gastrulation to epithelial 
differentiation. During the early embryogenesis, three germ layers are formed (1). Cells 
derived from the endoderm achieve hepatic competence leading to the rise of hepatoblasts (2). 
Hepatoblasts migrate into the septum transversum mesenchyme and proliferate rapidly, which 
is orchestrated by various signals (3). Hepatoblasts differentiate into cholangiocytes and 








Physiologically, the liver has an essential role in coordinating anabolic and catabolic 
reactions, homeostasis, and excretion of waste products in the human body [reviewed in 
(16)]. It orchestrates carbohydrate, amino acid, and lipid metabolism and participates in 
drug metabolism, detoxification, and secretion of xenobiotic substances. In addition to 
secreting numerous proteins such as coagulation factors, albumin, and insulin-like 
growth factor 1, the liver aids digestion through bile production. In collaboration with 
other organs, the liver controls body temperature and assists in the maintenance of blood 
volume. Certain minerals, such as iron and copper, are stored in the liver together with 
fat-soluble vitamins. During fetal development, the liver is also the main hematopoietic 
organ.   
The functional unit of the liver is a hexagonal structure called a lobule (Figure 3A), 
composed of hepatocyte cords covered with endothelial cells constituting sinusoids. 
Each hexagon corner contains a branch of the hepatic artery, portal vein, and bile duct, 
together forming a structure named the portal triad. Branches of the hepatic artery and 
portal vein drain blood to sinusoids; outflow from sinusoids collects in the central vein 
of each lobule and then into the hepatic veins. As a consequence of this structural 
organization, blood perfusion and metabolism are dissimilar in hepatocytes nearest to 
the portal triad versus those next to the central vein (17). The acinus is the smallest 
functional structure in the liver dividing hepatocytes in three zones depending on their 
position within the lobule.  
Figure 2. Segmental anatomy of the liver. Segment 1 is located on the posterior side of the 








1.4 Cellular anatomy and physiology 
Liver parenchyma is composed of polygonal-shaped hepatocytes comprising 
approximately 80 % of all the cells in the organ. The basal surface of hepatocytes faces 
the perisinusoidal space (Space of Disse) (Figure 3B) and associated liver sinusoidal 
endothelial cells (LSECs). The apico-lateral surface interacts with neighboring 
hepatocytes and bile ducts. This polarization has physiological significance; the apical 
surface mainly secretes bile, while the basal side is important for secretion and uptake 
of nutrients, hormones, and proteins to/from circulation. Key physiological processes 
involving hepatocytes are listed in Table 1.  
The liver has great regeneration potential, and in adult liver new hepatocytes are thought 
to arise from oval cells. These cells are bipotential liver progenitor cells which are able 
to differentiate into hepatocytes and cholangiocytes as response to injury [reviewed in 
(18)].  
The main non-parenchymal cell types in liver include cholangiocytes, Kupffer cells and 
other macrophages, LSECs, pit cells, and hepatic stellate cells (Figure 3B). Small 
populations of lymphocytes also reside in liver. 
Cholangiocytes are cuboidal-shaped epithelial cells forming bile ducts. They regulate 
bile composition and transport. LSECs are fenestrated cells forming sinusoids. Fenestrae 
and gaps between LSECs allow easy exchange of substances between hepatocytes and 
the blood stream. Kupffer cells responsible for front-line innate immune reactions 
constitute the major macrophage population in liver. Quiescent hepatic stellate cells 
Figure 3. Structure of the liver lobule and main cell types. A lobule is composed of 
hepatocyte cords lined with LSECs, a portal triad in each corner, and central vein in the middle 
(A). Hepatocytes, cholangiocytes, Kupffer cells, LSECs, and HSCs make up the vast majority 
of cells residing in the liver (B). Arrows indicate flow direction inside the structures (B). 




store lipids and vitamin A, and in response to inflammation these cells transform to
myofibroblasts.  
Recent single cell RNA sequencing studies have shown that liver cell types can be
further divided into discrete subpopulations; over 20 distinct cell types have been 
identified in the adult liver (19,20).
Table 1. Liver cell types and their role in the physiological processes. Table modified from (21).
Cell type Location in liver Physiology
Hepatocyte Parenchyma glucose/glycogen metabolism, 
cholesterol metabolism, bile 
secretion, xenobiotic 
metabolism, urea metabolism, 
blood clotting, acute phase 
response, protein secretion
Cholangiocyte Ductal epithelium bile duct structure, controls 
bile transport and flow rate, 
secrete water and bicarbonate
Liver sinusoidal endothelial 
cell
Sinusoids facilitate blood 
microcirculation by forming 
sinusoids, allow transfer of 
proteins and other molecules 
between blood and 
hepatocytes, cytokine 
secretion, blood clotting, 
immune responses
Endothelial cell Vasculature form blood vessels, contribute 
to hepatic zonation
Kupffer cell Sinusoids phagocytosis of foreign 
material, secretion of 
cytokines and proteases,
innate immunity
Hepatic stellate cells Perisinusoidal lipid, vitamin A, and retinoid 
storage, contribute to 
extracellular matrix 
maintenance and response to 
injury, secrete cytokines




2.1 Epidemiology and etiology
Hepatic neoplasms are rare in childhood, and malignant liver tumors account 
approximately 65 % of the cases [reviewed in (22)]. Hepatoblastoma (HB) is the most 
common liver cancer type among the infants and young children with an annual 
incidence of 1.9 patients per million (23). Between 1987 and 2016, the median HB 
incidence in Finland was 1.1 cases per million (24). Most cases of HB present before 5
years of age, and the median age at diagnosis is 1 year (23,25). Other primary liver 
malignancies in pediatric population include hepatocellular carcinoma (HCC), which 
typically occurs later in childhood, and sarcomas [reviewed in (26)]. Tumors having 
features of both HB and HCC exist, and these are classified as transitional liver cell 
tumors (27).
In most cases the etiology of HB is obscure, although histology and molecular landscape 
allude to a developmental origin [reviewed in (28)]. Male predominance has been 
observed in several studies (29,30). Certain genetic syndromes are associated with 
higher risk for HB, including Beckwith-Wiedemann syndrome, Sotos syndrome, 
familial adenomatous polyposis, and trisomy 18 (31–36).
Low birth weight is a clear risk factor for HB (37–40). Exposure to environmental 
factors during the perinatal period, such as pre-eclampsia, maternal tobacco 
consumption, and infertility treatments have been investigated as potential HB risk 
factors, but conclusions have been inconsistent (37,41,42).
2.2 Diagnosis
A palpable mass or abdominal swelling are the typical presenting signs of HB. Patients 
may also exhibit nausea, vomiting, weight loss, growth retardation, abdominal pain,
jaundice, or lethargy.
Serum alpha-fetoprotein (AFP) is commonly elevated in HBs and is a key tumor marker 
for diagnosis and surveillance. Some aggressive HBs, however, are associated low
serum AFP levels (43). Other serum biomarkers proposed for HB diagnostics include 
microRNA-21, glypican-3 (GPC3), hepatocyte derived lipocalin-2, and delta-like 1, but 
none of these is currently in widespread clinical use (44–47).
Radiological examination including ultrasonography, computed tomography, and 
magnetic resonance imaging are employed to evaluate tumor size and delineate affected 




HB histology is heterogenous. This heterogeneity is evident between tumors and even 
in different regions of the same tumor. Tumor cells may exhibit various differentiation 
stages, and tumors may include teratoid components. Generally HBs can be classified 
into two groups: pure epithelial (56 %) and mixed epithelial and mesenchymal tumors 
(44 %) (48,49).
Based on cell differentiation stage and growth pattern, pure epithelial HBs are further 
divided into five subtypes. Tumor components may resemble fetal or embryonal 
hepatoblasts, demonstrate loss of cell architecture characteristic for small-cell 
undifferentiated (SCUD) form, have macrotrabecular organization, or express 
cholangiocyte markers typical for cholangioblastic HB (50,51). Hepatoblasts produce 
AFP during normal liver development and this feature is present in a majority of HBs 
(52,53). Extramedullary hematopoiesis is commonly observed in fetal areas of HBs (54).
SCUD histology rising from poorly differentiated stem cells is associated with low AFP 
expression and serum concentration (43). Other markers suggested for histological 
evaluation of HBs include GPC3, β-catenin (CTNNB1), and integrase interactor 1 
(INI1) [reviewed in (55)]. 
In addition to epithelial components, HBs with mixed histology contain stromal 
derivatives, such as osteoid, cartilage, or spindle cells, with or without teratoids (54).
2.4 Molecular biology
Whole chromosome aneuploidies are frequent in HB. Genomic gains most often affect 
chromosomes 2, 8, and 20, whereas genomic losses are typically observed in 
chromosome 18 [reviewed in (56)]. Structural alterations are less common, though an 
unbalanced translocation involving long arm of chromosome 1 has been reported in 
several studies (57,58). Gains of chromosomes 8q and 2p are linked to aggressive form 
of HB (59).
HBs harbor a relatively low mutation burden, which is typical of other pediatric cancers. 
Deregulated pathways are associated with developmental signaling. WNT/β-catenin 
signaling is often aberrantly activated in cancer cells and promotes tumor progression 
by regulating proliferation, motility, and stem cell renewal [reviewed in (60)]. In HB, 
mutations in CTNNB1 gene encoding β-catenin are observed approximately in 65 % of 
cases (61,62). Mutations in other genes (AXIN2, DKK1, DKK3) related to WNT/β-
catenin pathway are also common (63,64). Additionally, upregulation of the WNT target 
gene MYC and HGF/c-MET mediated activation of β-catenin have been demonstrated 
in HBs (59,65,66).
Other developmental pathways implicated in HB pathogenesis include Hedgehog, IGF, 
and Hippo signaling. The Hedgehog pathway is activated during liver organogenesis, 
regeneration, and malignant transformation. The Hedgehog ligands GLI1 and PTCH1 
19 
 
are frequently overexpresed in HBs (67). Abnormal IGF-axis activity, including both 
altered expression of ligands and receptors, was demonstrated in the study by Gray et al
(68). Hippo signaling mediator YAP1 has been observed to be overexpressed in large 
set of HBs, and enforced upregulation of YAP1 in mouse model led to rapid HB
formation (69).
There is increasing evidence that certain epigenetic and genetic signatures are associated 
with HB pathogenesis and prognosis. Cairo et al. identified a signature of 16-genes 
(Table 2) that can be utilized in HB risk assessment (59,70). Two distinct epigenomic 
subtypes of HB have been demonstrated recently (71).
Table 2. 16-gene signature associated with poor prognosis in HB (70).

















2.5 Risk stratification and prognosis
Radiological pre-treatment extent of disease (PRETEXT) staging is used to assess tumor 
distribution before treatment initiation. Based on affected liver segments, tumors are 
staged PRETEXT I-IV (Figure 4) (72). PRETEXT stages are supplemented with 
annotation factors describing involvement of hepatic vasculature (V, P), extrahepatic 
growth (E), multifocal nodes (F), tumor rupture at diagnosis (R), or metastasis (M). 
According to the Children's Hepatic tumors International Collaboration coalition, HBs 
grouped in PRETEXT III or IV diagnosed in older children (>3 years) or metastasis or 
low AFP concentration (≤100 ng/ml) with any PRETEXT stage are categorized as high 
risk tumors (73). If any VPEFR annotations are involved, tumors belong to intermediate 
or high-risk group depending on patient age. Young age correlates with lower risk in all 
PRETEXT classes. Five-year event-free survival is demonstrated to be over 80 % in all 
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PRETEXT groups if there is no metastasis or VPEFR involved, patient is younger than 
3-year old at diagnosis, and AFP > 1000 ng/ml. Event-free survival decreases drastically 
when metastasis is present, being less than 50 % in five-year period.  
Tumor histology also has been associated with prognosis: pure fetal HBs are linked to 
better overall survival and in some cases these tumors can be resected without 
chemotherapy (74). Less differentiated and especially SCUD histology have been 








Complete resection of tumor is a mainstay of HB treatment and is supported by pre- and 
post-operative chemotherapy. Cisplatin monotherapy is recommended for standard risk 
patients (76). Patients with more advanced disease are treated with “superPLADO” 
(cisplatin alternating with carboplatin and doxorubicin) or cisplatin/doxorubicin therapy 
according to SIOPEL (Childhood Liver Tumors Strategy Group) protocols (77,78). 
Additionally, there are ongoing clinical trials assessing the efficacy of vincristine, 
etoposide, irinotecan, 5-fluorouracil, gemcitabine, oxaliplatin, and sorafenib alone or 
combined with current treatments (clinicaltrials.gov study ID: NCT03017326). Pre-
operative chemotherapy aims to shrink the tumor thereby enabling surgical resection. If 
the tumor remains unresectable, liver transplantation is performed if limiting risk factors 
(extrahepatic disease) are not present. Overview of HB management is presented in 
Figure 5. 
 
Figure 4. Radiological PRETEXT staging describes which liver sections are affected by 
tumor. PRETEXT I includes situations when tumor is only in one section (RPS or LLS) and 
there are three tumor-free adjoining sectors (A). Tumors affecting on two sections or CL, RAS, 
or LMS alone are staged PRETEXT II (B). PRETEXT III tumors involve three sectors and there 
are no tumor-free adjoining sectors (C). When all the sectors are affected (with or without CL), 
tumors are staged PRETEXT IV (D). RPS=right posterior section. RAS=right anterior section. 




























Figure 5. Schematic view of the HB management. Abnormal function and mass in the 
abdominal area rises a suspicion of HB which is confirmed with laboratory tests (including 
serum AFP), CT or MRI scan, and histological analysis of tissue biopsy sample (left and middle 
panel). Surgical treatment combined with chemotherapy forms the cornerstone of HB treatment 





3.1 Structure and function 
Neuropilins (NRPs) are single-passing type I transmembrane glycoproteins acting 
typically as co-receptors enforcing the signal transduction (79). NRP family is composed 
of two members, NRP1 and NRP2, sharing approximately 45 % of sequence homology 
at amino acid level (Figure 6) [reviewed in (80)]. In humans, NRP1 gene is located in 
the short arm of chromosome 10 (10p11) and NRP2 gene is mapped to the long arm of 
chromosome 2 (2q34) (81). Common structure of NRPs contains seven domains: two 
complement (CUB) domains (a1 and a2), two coagulation factor (FV/FVIII) domains 
(b1 and b2), MAM domain (c), transmembrane domain (tm), and cytoplasmic domain 
(cyto) (82) (Figure 6). In addition to membrane-bound NRPs, alternative splicing results 
also in truncated soluble NRP isoforms lacking MAM, transmembrane and, cytoplasmic 
regions (83–85).  
NRPs have role in multiple physiological and pathological processes due to their 
versatile co-receptor and ligand assortment. They were originally documented as 
regulators of neural and vascular development interacting with plexins and vascular 
endothelial growth factor receptors (VEGFR). NRP2 has also a crucial role in formation 
of small lymphatic vessels (86). Transgenic mouse model deficient both for NRP1 and 
NRP2 (NRP1-/- and NRP2-/-) demonstrates severely abnormal vascular phenotype and 
embryonic lethality is observed before mid-gestation (E8.5) (87). In addition to neural, 
vascular, and lymphatic systems, postnatal NRP expression has been discovered in 
various organs including pancreas (pancreatic islet neogenesis), lung (homeostasis of 
alveolar epithelium), liver (activation of HSCs during the liver regeneration), and 
thymus (activation of T cells) (88–91). Ligands involved in these processes encompass 
platelet derived growth factor (PDGF), VEGFs, and semaphorins (SEMA).  
 
 
Figure 6. Structure of NRPs. NRPs are 
composed of seven domains including two 
CUB domains (a1-a2), two FV/FVIII domains 
(b1-b2), MAM domain (c), transmembrane 
domain (tm), and cytoplasmic domain (cyto). 
Percentages describe the sequence homology 
in each structural region. 
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3.2 NRP expression and role in cancer
Abundant NRP1 and/or NRP2 expression has been detected in various solid tumors 
including pancreatic adenocarcinoma, non-small cell lung cancer, ovarian carcinoma, 
colon cancer, glioma, neuroblastoma, and HCC (92–99). Mechanistically, NRPs are co-
operating with multiple cancer-related signaling pathways (Figure 7) encompassing 
VEGFRs, PDGFR, hepatocyte growth factor (HGF)/c-MET, TGFβR, and integrins 
[reviewed in (100)]. 
NRPs are involved in several pro-tumorigenic processes such as proliferation, epithelial-
mesenchymal transition (EMT), vascular remodeling, metastasis formation, and 
chemoresistance [reviewed in (101)]. Additionally, animal studies have shown that 
blocking NRP function reduces cancer growth and metastasis in tumor models including 
HCC, glioma, and  colorectal carcinoma (102–104). Investigations have demonstrated 
that NRPs can be utilized also as delivery target for conventional agents such as cisplatin 
and doxorubicin aiming to increase the treatment specificity and efficacy (105,106).
Figure 7. Overview of the NRP signaling in tumor cells. NRPs are typically acting as
enhancing co-receptors for multiple cancer related players such as VEGFR2, PDGFR, c-
MET/HGFR, TGFβR, and integrins. Figure was created with BioRender.com.
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4 INNOVATIVE APPROACHES IN CANCER TREATMENT
4.1 Drug re-purposing
Drug re-purposing is a strategy to overcome the slow pace and high cost of discovering 
new treatment compounds by evaluating drugs already accepted for some other 
indication for novel purposes [reviewed in (107)]. As the safety is already evaluated 
during the original market approval process, re-purposed drugs can proceed to phase 2 
clinical trials faster than new compounds. Typically “old” drugs are also more cost-
effective than novel treatments, which is beneficial from both patient and society point 
of view. 
In oncology, drugs evaluated for cancer treatment represent multiple categories such as
non-steroid anti-inflammatory, anti-fungal, vasodilating, antimalarial, and 
antidepressant agents [reviewed in (108)]. One of widely studied drugs is chloroquine 
(CQ) which is a classical anti-malarial drug. It has demonstrated anti-tumorigenic 
actions in various solid cancer types including HCC, pancreatic adenocarcinoma, colon 
cancer, and glioblastome multiforme (109–112). Furthermore, conventional 
chemotherapy combined with CQ has shown increased anti-tumor efficacy in several 
cancer cell models, and this approach has been tested also in clinical use for glioblastoma 
multiforme (113–115).
4.2 Targeted therapies
Conventional cancer therapy is based on cytotoxic chemotherapeutic agents, such as 
platinum-derivatives and doxorubicin which are utilized in HB management. The major 
problem in this approach is a multiorgan toxicity as the cellular targets are also widely
present in healthy cells (116–118).
Gene and protein expression in cancer cells and their surroundings is remarkably 
different compared to normal cells. By identifying these molecular alterations, 
therapeutic modalities targeting tumor specific features have been discovered. Targeted
therapies have potential to be less toxic for healthy cells than traditonal cytotoxic agents
as their effect is limited mainly to the tumor and its microenvironment [reviewed in 
(119)]. Additionally, conventional cytotoxic drugs may be conjugated with tumor-
targeted molecule which has the potential to increase specificity. An overview of the 








4.3 Monoclonal antibodies 
Monoclonal antibodies commonly target proteins located on the extracellular side of the 
cell membrane. These targets include membrane-bound receptors, soluble receptors, and 
circulating signaling molecules. Mechanism of action can be based on direct disruption 
of tumor cell function (e.g., inhibition of survival signals) or it can be executed 
undirectly through immune response activation (e.g., antibody dependent cellular 
cytotoxicity) [reviewed in (120)].  
Overexpression of epithelial cell adhesion molecule (EpCAM) has been observed in 
HBs (121), and Armeanu-Ebinger and colleagues suggested that targeting EpCAM with 
monoclonal antibody may be beneficial in HB treatment (122). 
 
4.4 Small molecules 
Small molecule (<900 Da) drugs are typically able to penetrate into cells which allows 
targeting to intracellular proteins. Common targets include proteins involving cell cycle 
Figure 8. Molecular targeting in cancer cells and tumor microenvironment. Targeted 
therapies can be focused on either directly to the tumor cells or cells residing in the 
microenvironment. TAM=tumor associated macrophage. CAF=cancer associated fibroblast. 
Figure was created with BioRender.com. 
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coordination (e.g., CDK inhibitors), dysfunctional apotosis (e.g. BAX agonists), and 
aberrant DNA-damage repair response (e.g., PARP inhibitors) (123–125).
In HB, the PLK1 inhibitor volasertib and proteasome inhibitor bortezomib have been 
shown to have efficacy in pre-clinical studies (126,127). Monotherapy with 
multikinase inhibitor sorafenib has been tested for refractory HB with encouraging 
results in case study Shanmugam et. al (128).
4.5 Gene therapy and cancer vaccines
Gene therapy aims to modify, inhibit, or activate gene expression to the direction which 
is harmful for the cancer cells. This can be carried out utilizing multiple methods 
including oncolytic viruses, RNA interference, CRISPR-Cas9 mediated gene editing,
and oligonucleotide therapeutics [reviewed in (129)]. RNA interference therapy 
employs small RNA molecules to regulate gene expression and CRISPR-Cas9 is able 
to edit gene structure specifically enabling replacement of the unfunctional gene
(130,131).
Lu et al. published recently results from first human trial employing CRISPR technology 
in cancer treatment. They observed a relatively low rate of off-target effects increasing 
the potential of CRISPR as a future cancer therapeutic modality (132). MicroRNA 
therapies have been tested in pre-clinical studies for HB treatment including targeting to 
microRNA-4510 and microRNA-624-5p (133,134).
Cancer vaccines aim to stimulate T cell mediated immune response against tumor cells.




AIMS OF THE STUDY
This doctoral thesis focuses on molecular mechanisms in the HB pathobiology. 
The specific aims of studies presented in this thesis are:
1. To elucidate the role of transcription factor GATA4 in HB pathogenesis and 
identify the genes associated with GATA4.
2. To assess the expression pattern of neuropilin-2 in HB and investigate its 
potential as a treatment target.
3. To evaluate the efficacy of chloroquine in HB cells and enlighten its 




1 Patient samples and clinical data (I, II)
HB patients included in this study were treated at Children’s Hospital in Helsinki 
University Hospital between January 1st, 1990 and December 31st, 2017. Samples were 
originally collected during the diagnostic procedures or surgical treatment. Normal liver 
control samples were obtained from organ donors. Clinical data was acquired from 
patient medical record system of Helsinki University Hospital. This study was approved 
by board of Helsinki University Hospital Ethical Committee (98/13/03/03/2013, 
HUS/3319/2018) and Finnish National Authority of Medicolegal Affairs and Health 
(THL/1239/5.05.01/2015). 
2 Cell cultures
2.1 Cell lines (I, II, III)
Eight human HB cell lines were utilized in studies included in this thesis. Characteristics 
of each cell line are described in Table 3. Immortalized HUH6 cell line was purchased 
from Japanese Collection of Research Bioresources Cell Bank (Osaka, Japan) and 
HepG2 was a kind gift from Professor Timo Otonkoski (University of Helsinki, 
Finland). Cell lines established from patient-derived xenografts (PDXs; HB-243, HB-
279, HB-282, HB-284, HB-295, HB-303) were obtained through collaboration with 
XenTech (Evry, France). HUH6 and HepG2 cells were maintained in Dulbecco’s 
Modified Eagle’s Medium (DMEM)-glutaMAX supplemented with 10 % fetal bovine 
serum (FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin sulfate (all from Gibco, 
Waltham, MA, USA). Cell lines established from PDX models were maintained in 
Advanced DMEM:F12 supplemented with 8 % FBS, 2 mM glutaMAX, 100 U/mL 
penicillin, and 100 μg/mL streptomycin sulfate, and 20 μM rock kinase inhibitor Y-
27632 (S1049; SelleckChem, Houston, TX, USA). All the cell lines were routinely 




Table 3. Characteristics of the cell lines. 
Cell line Age at sampling Sex Histology Origin Reference Article





tumor (136) I, II, III
HepG2 15 years male epithelial primary tumor (137) I
HB-243 52 months male embryonal extrahepatic residual (126) II, III
HB-279 79 months male embryonal and macrotrabecular
primary 
tumor (126) II, III
HB-282 12 months male embryonal primary tumor (126) II, III
HB-284 83 months male embryonal peritoneal metastasis (126) II, III
HB-295 26 months female fetal primary tumor (126) II, III
HB-303 69 months female fetal primary tumor (138) II, III
2.2 Primary hepatocytes (I, II)
Cryopreserved primary hepatocytes from donors (51-year old Caucasian male and 4-
year old Caucasian male) with non-liver related causes of death were purchased from 
commercial provider (Lonza, Basel, Switzerland). Cells were cultured on collagen I -
coated plates as monolayers and maintained in HBM™ Basal Medium supplemented 
with transferrin, ascorbic acid, epidermal growth factor, insulin, hydrocortisone, fatty-
acid free bovine serum albumin, 30 mg/ml gentamicin and 15 μg/ml amphotericin (all 
from Lonza).  
2.3 Spheroid cultures (III)
Cells were seeded (3000 cells/well) into CellCarrier ultra-low attachment surface 96-
well plates (PerkinElmer, Waltham, MA, USA). Spheroids were kept undisturbed for 72 
h to establish the three-dimensional (3D) structure. After the initiation period, imaging 
and treatments were conducted. 
3 Manipulation of gene expression (I, II)
Prior disturbing the gene expression of GATA4 or NRP2, the cells were seeded at density 
to reach 70-80 % confluency at the time of transfection. 
3.1 Small interfering RNA transfections (I, II)
Small interfering RNA (siRNA) transfections were used to downregulate expression of 
selected genes in HB cell cultures. HUH6 (I, II) and HepG2 (I) cells were treated with 
ON-target Plus SMARTpool siRNAs (Dharmacon, Cambridge, UK) at a final 
concentration of 100 nM.  RNAiMAX lipofectamine reagent (Thermo Fisher Scientific, 
Waltham, MA, USA) diluted in OptiMEM medium (Gibco) was used to deliver siRNAs 
into the cells. Non-targeting (NT) siRNAs were used as a control treatment. 
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3.2 Plasmid transfections (I)
Primary hepatocytes were transfected with pMT2-GATA4 (139) or pMT2 control 
plasmid to enforce overexpression of GATA4. Plasmids were delivered into the cells 
utilizing jetPEI™ Hepatocyte DNA transfection reagent diluted in OptiMEM medium
(Gibco).
5 RNA expression analysis
4.1 RNA extraction and real-time quantitative PCR (I, II)
RNA was extracted utilizing NucleoSpin RNA/Protein kit (Macherey-Nagel, Düren, 
Germany) and reverse transcription was carried out with Reverse transcriptase core kit 
(Eurogentec, Seraing, Belgium). Mesa Green qPCR MasterMix Plus SYBR assay
(Eurogentec) was employed to carry out real-time quantitative PCR (RT-qPCR). 
Geometric mean of PPIG and GAPDH expression was used as reference. Primer 
sequences are given in Table 4.
Table 4. RT-qPCR primer sequences.
Gene symbol Oligonucleotide sequence (5’ → 3’) Reference
ADD3 F: GGCTCTGCGGCGCTTA R: CTTGTTATCTCGCAGCGCG NM_016824.4
AHNAK F: CTCGTCGCCGCCAGTAG     R: TCTCGGTCACAACCTGAGG NM_001620.2
CDH1 F: CACCACGGGCTTGGATTTTG R: TGGGGGCTTCATTCACATC NM_001317184.1
CDH2 F: GCGTCTGTAGAGGCTTCTGG R: GCAGTTGCTAAACTTCACATTGA NM_001792.4
COL4A2 F: GGATGGCTATCAAGGGCCTG R: CTGGCACCTTTTGCTAGGGA NM_001846.3
FN1 (MSF) F: CCCATCCAGTGGAATGCACC R: GGTGGGATACTCACAGGT NM_054034.2
GAPDH F: GGTCATCCATGACAACTTTGG R: CCATCCACAGTCTTCTGG NM_004792.2
GATA4 F: CTCCTCTGCACATTGCTGTT R: GTGTGGGGAGGCGTAGT NM_002052.3
IGFBP1 F: TTTAGCCAAGGCACAGGAGA R: ATGGATGTCTCACACTGTCTG NM_000596.2
MMP1 F: AGTCCAGAAATACCTGGAAAAATAC R: TTTTTCAACCACTGGGCCAC NM_002421.3
NRP2 F: CTGTGGGTCATCCGTGAGGAC R: ATGGGTTCCATGCAGTTCTCCAG NM_201266.2
PPIG F: CAATGGCCAACAGAGGGAAG R: CCAAAAACAACATGATGCCC NM_004792.2
RHOB F: GTGTGTCTGTTCGACTCCCC R: AGGGATATCAAGCTCCCGC NM_004040.3
RHOU F: TGCCGGACAGGATGAATTTGA R: TGGGACAGTGGCATCGAAT NM_021205.5
SRC F: CAGATTGTCAACAACACAGAGGG R: CACGTAGTTGCTGGGGATG NM_004040.3
SYTL2 F: AGTGAAGGCTCGCAACGC R: CACCTACCTCCGAGTCG NM_032943.4
TIMP2 F: CAGATGTAGTGATCAGGGCCAA R: CCTTCTCAGGCCCTTTGAA NM_003255.4
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4.2 In situ hybridization (I)
RNAscope Multiplex Fluorescent Reagent kit (v2, #323100; ACDBio, Milano, Italy) 
was employed for RNA in situ hybridization target detection. Paraffin-embedded 
formalin-fixed samples (5 μm thick) were baked at 60 °C for 1 h and then deparaffinized 
followed by hydrogen peroxidase treatment (10 min at RT). Target retrieval was carried 
out at +97 °C for 15 min and subsequently samples were treated with protease at +45 °C 
for 15 min. Probe hybridization (GATA4 #579821) was performed at 40 °C for 2 h 
followed by signal amplification. Following fluorophores (PerkinElmer) were used at 
1:1500 dilution for each: TSA Plus Cyanine 3 (NEL744001KT) and TSA Plus Cyanine 
5 (NEL745001KT). DAPI was used to counterstain the sections. 
Images were captured with 3DHISTECH Panoramic 250 FLASH II digital slide scanner 
at Genome Biology Unit (Research Programs Unit, Faculty of Medicine, University of 
Helsinki Biocenter, Helsinki, Finland).
4.3 RNA microarray (I)
HUH6 cells were transfected with GATA4 or NT control siRNA and incubated for 72 h. 
RNA was extracted (Nucleospin RNA/Protein kit) and subsequently purified 
(Nucleospin RNA Clean-up XS kit, Macherey-Nagel) for the further processing. Two 
set of samples were collected from different passages (3+3 in each group). RNA quality 
was measured with Bioanalyzer (Agilent, CA, USA) and following all the samples were 
hybridized on Illumina Human HT-12 v4 oligonucleotide expression BeadChip 
(Illumina, San Diego, CA, USA) at Functional Genomics Unit (University of Helsinki). 
Background corrected raw data processed with BeadStudio software (Illumina) was 
quantile normalized and log transformed utilizing BedArray Bioconductor package 
(140). Differentially expressed genes were identified with LIMMA tool (141) with
Benjamini-Hochberg correction and filtered by cut-off criteria false discovery rate 
(FDR) < 0.05 and lg2 fold change (FC) ± 0.2. 
4.4 RNA sequencing data analysis (I, II)
Datasets with accession numbers as follows were downloaded from GEO database of 
National Center for Biotechnology Information (142) or EGA European Genome-
phenome Archive (https://ega-archive.org/): GSE83518 (HUH6), EGAS00001004827 
(HB-243, HB-279, HB-282, HB-284, HB-303), and GSE140520 (primary hepatocytes). 
Data was pre-processed utilizing Trimmomatic (143) and following aligned with 
reference genome (Homo_sapiens.GRCh38.9) using HISAT2 tool (144). Differentially 
expressed genes were identified employing edgeR package (145) and then filtered using 
cut-off criteria false discovery rate (FDR) < 0.05 and lg2 fold change ±1 .  
4.5 RT2 Profiler death pathway finder array (III)
Expression of 84 death signaling associated genes was explored utilizing RT2 Profiler 
death pathway finder array (330231/PAHS-212ZA; Qiagen, Valencia, CA, USA) 
following manufacturer’s instructions. Data was analyzed with GeneGlobe software 
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(Qiagen) and geometric mean of B2M, HPRT1, and GAPDH was used to normalize gene 
expression. 
5 Protein expression analysis
5.1 Protein extraction and western blotting (I, II, III)
Total protein was isolated using the Nucleospin RNA/Protein kit (Macherey-Nagel). 
Proteins were separated with electrophoresis utilizing Mini-Protean TGX Stain-Free 
Gels (Bio-rad, Hercules, CA, USA) and transferred to PVDF membrane. Non-specific 
binding was blocked with 5 % fat-free milk in Tris-buffered saline with Tween 20. 
Primary antibody incubations were carried out at +4 °C for overnight and secondary 
antibody incubations were performed at room temperature for 1 h. Protein bands were 
visualized utilizing Enhanced Chemiluminescence detection kit (Amersham ECL 
reagent; GE Healthcare, Barrington, IL). Band intensities were normalized to the total 
protein amount in the corresponding lane exploiting Stain-free technology (146).
Quantification was carried out with ImageLab software (version 6.0.1; Bio-Rad).  
5.2 Immunohistochemistry (I, II)
Paraffin-embedded formalin-fixed patient samples in 5-μm sections were 
deparaffinized, hydrated, and then treated with target retrieval solution for 35 min at +98 
°C (pH 9; Dako, Glastrup, Denmark). Hydrogen peroxidase (3 %) was used to avert 
endogenous peroxidase activity and 0.4 % casein was utilized to block unspecific 
binding (both solutions from Novolink Polymer Detection System Kit; Leica, 
Newcastle, UK). Primary antibodies were incubated either at room temperature for 1 h 
(NRP1) or at +4 °C for overnight (NRP2, GATA4). Novolink Polymer (Leica) and DAB 
substrate (Vector laboratories, Burlingame, CA, USA) were used to visualize protein 
expression. Primary antibody was replaced with non-immune serum in control 
experiments. Scoring was performed by two independent investigator. Antibody details 
are described in Table 5.
Images were captured with 3DHISTECH Panoramic 250 FLASH II digital slide scanner 
at Genome Biology Unit (Research Programs Unit, Faculty of Medicine, University of 
Helsinki Biocenter, Helsinki, Finland).
5.3 Immunofluorescence (I, II, III)
Cells were cultured on Matrigel or collagen I coated chamber slides for 
immunofluorescence experiments. For basic immunofluorescence staining, cells were 
fixed and permeabilized with ice-cold methanol. Unspecific binding was blocked with 
UltraVision Protein Block solution (Thermo Fisher Scientific). Primary antibody 
incubations were carried out at room temperature for 1 h. Next, samples were incubated 
with secondary antibody for 1 h in the dark. Mounting was performed with DAPI 
containing mounting medium to counterstain the nuclei. 
Phalloidin staining was carried out per manufacturer’s instructions. Briefly, cells were 
fixed with 4 % paraformaldehyde (PFA), permeabilized with Triton-X, and incubated 
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with UltraVision Protein Block Solution (Thermo Fisher Scientific). Antibody 
incubation was performed at room temperature for 1 h and samples were protected from 
light during the experiment. 
Imaging was aquired with Zeiss Axio Imager M2 (Carl-Zeiss, Oberkochen, Germany).
Detailed information of antibodies is given in Table 5.
Table 5. List of antibodies.
Antibody Host/source Cat.no Manufacturer Method (concentration)
Anti-mouse 
IgG-Alexa488
donkey A21202 Life Technologies IF (1:200)
Anti-rabbit 












ImmunoResearch WB (1:10 000)











IF (1:200) WB 
(1:1000)
NRP1 rabbit ab81321 Abcam IHC (1:3000) WB (1:1500)
NRP2 mouse sc-13117 Santa Cruz IHC (1:2000) WB (1:800)
PARP1 rabbit 9532 CellSignaling Technologies
WB (1:1500) IF 
(1:800) 




phalloides P5282 Sigma Aldrich IF (1:250)
IF=immunofluorescence. IHC=immunohistochemistry. WB=western blotting. 
6 Functional studies
6.1 Cell viability (II, III)
Cell viability was assessed with two methods: tetrazolium salt-based WST-1 reagent 
(Roche Molecular Biochemicals, Mannheim, Germany) and ATP-based assay 
(PerkinElmer, Waltham, MA, USA). Cells were incubated with WST-1 reagent for 2 h 
and absorbance was measured at 450 nm with Multiskan FC Plate reader (Thermo Fisher 
Scientific). For ATP measurements, cells were lysed and incubated with ATP substrate 
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following manufacturer’s instructions. Luminescence was metered with Enspire 
Multimode Plate reader (PerkinElmer). 
6.2 Clonogenic assay (III)
Cells were plated at low density 24 h prior the chloroquine treatment initiation. 
Treatments were replaced daily and in the end of experiment cells were stained with 
crystal violet. Plates were imaged with ChemiDoc XRS+ Imaging System (Bio-Rad) 
and number of colonies was determined with ColonyArea Plugin in ImageJ (147).
6.3 Caspase activity assay (III)
Amount of apoptosis effector proteins caspase 3 and 7 (Caspase 3/7 Glo, Promega) were 
measured to assess the activation of apoptotic process. Cells were incubated with 
caspase 3/7 substrate for 2.5 h and luminescence was measured with Enspire Multimode 
Plate reader (PerkinElmer). 
6.4 Migration studies (I, II)
Cell migration was evaluated with two different methods. For the wound healing assay 
(I), cells were cultured as a confluent monolayer on collagen I coated 6-well plates. A 
wound was made with 120 μl pipette tip and medium was replaced after scratching. 
Imaging was performed at the initiation and after 24h. The velocity of migratory front 
was calculated with ImageJ software (148).
Transwell assay (I, II) was performed utilizing migration inserts (pore size 8 μm; Merck 
Millipore, Darmstedt, Germany) placed into 24-well plates. Bottom of each insert was 
pre-coated with collagen I. Cells were seeded into inserts in serum-free medium and 
outside of the insert was normal cell culture medium. Cell were allowed to migrate for 
40-42 h after which the inserts were fixed with PFA, permeabilized with 100 % 
methanol, and stained with crystal violet. Five randomly chosen fields of each insert 
were imaged and number of migrated cells was counted utilizing ImageJ (148).
7 Chloroquine administration (III)
Chloroquine diphosphate (CQ, ab142116; Abcam) was dissolved in sterile water as 10 
mM stock solution. Further dilutions (1 μM, 5 μM, and 10 μM) were prepared in the 
adequate cell culture medium. CQ was administrated for 4-14 days an experiment-
dependent manner and treatments were refreshed daily. Cell culture medium without 
CQ was used as a control treatment.  
8 Metabolism studies
8.1 Metabolomic profiling (III)
Cell pellets (1.5 x 106 cells/sample) were snap-frozen in liquid nitrogen and subjected 
to metabolomic profiling utilizing Acquity UPLC-MS/MS system and XEVO TQ-S
Triple Quadrupole LC/MS system (Waters Corporation, Milford, MA, USA). Web-
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based software MetaboAnalyst 4.0 (http://www.metaboanalyst.ca) (149) was employed 
to analyze normalized concentrations of 100 metabolites. 
8.2 Aspartate rescue experiment (III)
Cells were treated either with 5 μM CQ, 10 mM aspartic acid (Sigma Aldrich), CQ + 
aspartic acid, or with control treatment. Cell viability after 96 h treatment period was 
assayed with ATPlite kit (Perkin Elmer) and luminescence was measured with Enspire 
Multimode Plate reader (Perkin Elmer). 
8.3 NAD/NADH assay (III)
NAD/NADH assay kit was obtained from Abcam. HUH6 cells were cultured with or 
without CQ and after 96 h they were lysed. Processing was performed as described in 
(150) and samples were incubated for 1.5 h at room temperature. Absorbance was 
measured with FC Multiskan Microplate reader (Thermo Fisher Scientific). Normalized 
concentrations were utilized to calculate NAD/NADH by equation ([NADtotal—
NADH])/[NADH].
9 Statistical analyses
Three independent experiments were carried out for all the in vitro experiments if 
otherwise has not stated. Student’s t-test or ANOVA followed with Dunnet’s test was 
utilized to assess statistical significancy. Statistical significancy was set to p-value < 
0.05. For RNA sequencing and mRNA microarray, statistical methodology is described 




1 GATA4 as a regulator of epithelial-mesenchymal transition in 
hepatoblastoma cells (I)
 
1.1 GATA4 expression in HB patient samples and cell lines
Aberrant activation of developmental pathways is a well-recognized feature of HB 
molecular pathogenesis (reviewed in 9). Transcription factor GATA4 is crucial for early 
liver development and its abnormal expression has been linked to pro-tumorigenic 
processes in several cancer types (152–154).
An earlier study by Soini et al. demonstrated that GATA4 is abundantly expressed in 
HBs (155), but its role in HB pathogenesis has not been fully clarified. In this study we 
confirmed GATA4 expression in HBs using additional methodology and larger sample 
set (n=24) that was included in the previous study. RNA in situ hybridization 
demonstrated GATA4 mRNA expression in HB cells while low or negligible amounts 
were detected in the healthy hepatocytes (Figure 9A, C). At the protein level, GATA4 
expression was restricted to Kupffer cells and LSECs in the normal liver (NL) which is 
consistent with previous findings (155,156). Most HBs (83 %) showed moderate or high 
GATA4 protein expression localizing especially to embryonal areas of the tumor 
(Figure 9D) whereas 17 % of samples had low or negative GATA4 immunoreactivity. 
We did not observe any correlation between GATA4 expression and PRETEXT stage 
though the number of patients in each group was relatively low to reach statistical power 
(PRETEXT II n=7, PRETEXT III n=9, PRETEXT IV n=8).  
RNA sequencing data analysis revealed GATA4 overexpression in 5 PDX-derived HB 
cell lines, 4.1-8.2 -fold increase compared to primary hepatocytes, respectively (Eloranta 
et al., unpublished data, Figure 9E). Similarly, high GATA4 expression has been 





1.2 RNA interference mediated GATA4 silencing in HB cells 
GATA4 upregulation has been associated with tumor cell plasticity, increased 
chemoresistance, escape from programmed cell death, and proliferative phenotype in 
cancer cells (152,154,157). Based on these observations, we hypothesized that extensive 
GATA4 expression promotes malignant behavior in HB. To elucidate mechanisms by 
which GATA4 acts in HB pathogenesis, the immortalized HUH6 cell line was 
transfected with GATA4 or non-targeting control siRNA. With this method, GATA4 
expression decreased approximately 80 % at the mRNA level (Figure 10A). A drastic 
decrease in GATA4 immunoreactive nuclei was also observed indicating that gene 
silencing leads to reduced protein expression (Figure 10B-E).  
At the time this study was carried out, the number of commercially provided HB cell 
models was extremely limited. Thus, in vitro experimentations were conducted mainly 
utilizing HUH6 cell line representing mixed epithelial subtype of HB. Considering the 
broadly heterogenous nature of HB, GATA4 may have dissimilar roles in different HB 
subtypes limiting the applicably of results in this study. Furthermore, tumors are 
composed of variety of cell types and interactions between tumor cells and 
microenvironment cannot be mimicked in traditional cell cultures.  
 
Figure 9. GATA4 expression in HB tissue samples and PDX-derived cell lines. RNA in 
situ hybridization and IHC showing localization of GATA4 in NL (A-B) and HB (C-D). 
Arrow indicates GATA4 positive Kupffer cells in NL and black arrowhead points out 
GATA4 negative healthy hepatocytes (B). White arrowhead shows nuclear GATA4 
expression in HB (D). RNA-sequencing demonstrated overexpression of GATA4 in HB cell 





1.3 Global transcriptomic changes after GATA4 silencing in HB cells 
 
To explore global gene expression alterations associated with GATA4 in HB, we carried 
out an mRNA microarray hybridization on HUH6 cells with intact or silenced GATA4 
expression. Samples were collected from two different passages (3+3 / group) to 
minimize biases caused by transformation during passaging. Genes which were 
differentially expressed in both sample sets were included in the further analysis. We 
observed 106 differentially expressed genes (filtered by adjusted p-value < 0.05, lg2 
FC± 0.2) in GATA4 silenced cells versus NT siRNA treated cells of which 72 were 
downregulated and 34 were upregulated (Figure 11).  
 
Surprisingly, the magnitude of single gene alterations was relatively small (fold changes 
were between 0.5-1.45). Based on animal studies, it has been suggested that GATA6 
could compensate partial loss of GATA4 during the early liver development (3,159). In 
addition to GATA4 upregulation, aberrant GATA6 expression has been reported in HBs 
(155). If GATA6 is partially regulating same target genes than GATA4 in HUH6 cells, 
this may explain why we did not observe more drastic changes in the global 
transcriptome. 
 
Figure 10. GATA4 silencing in HUH6 
cell line. RNA interference mediated 
gene silencing decreased GATA4 
expression approximately 80 % at the 
mRNA level measured with RT-qPCR 
(A). GATA4 mRNA expression is a mean 
± SD of three independent experiment 
and represented as a relative value (**p-
value<0.01). HUH6 cells treated with 
NT control siRNA demonstrated strong 
nuclear GATA4 expression (C). GATA4 
intensity and number of positive cells 
decreased drastically after GATA4 
knockdown (E). DAPI was utilized as a 
nuclear counterstain (B, D). Scale bar: 









1.4 Over-representation of epithelial-mesenchymal transition associated genes in 
GATA4 knockdown HB cells 
 
Computational gene ontology (GO) enrichment analysis (160) highlighted abundancy 
of the gene sets related to developmental processes, cell adhesions, motility, or polarity 
(Figure 12) in microarray of GATA4 silenced cells. All the aforementioned biological 
processes are associated with epithelial-mesenchymal transition (EMT) [reviewed in 
(161)].  
 
EMT is a dynamic and reversible process that converts stationary polarized epithelial 
cells to motile mesenchymal cells. In brief, through genetic re-programming epithelial 
cells gradually lose apico-basal polarity and cell-to-cell junctions, re-organize the 
cytoskeleton, and adjust extracellular matrix composition to support migration and 
invasion in transformed mesenchymal cells (162). Physiologically, EMT plays 
important part in the early embryonic development and later it occurs during the wound 
healing. In the context of cancer, EMT facilitates malignant progression by enabling 
tumor cells to spread and invade from the original location to surrounding areas and 
subsequently occupy distant sites [reviewed in (163)].  
Figure 11. Differentially expressed genes (top 50) 72 h after GATA4 silencing in HUH6 cells. 
Results are filtered by adjusted p-value (<0.05) and clustered utilizing 2-dimensional hierarchical 
clustering approach. NT=non-targeting siRNA. G4=GATA4 siRNA.  
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Taken together, considering the role of GATA4 during the embryogenesis, GATA4 
overexpression may maintain aberrant activation of developmental processes, such as 
EMT, as suggested by our data. This observation is also supported by recent study 
linking GATA4 overexpression with EMT-related genes and processes in 
nasopharyngeal cancer (152).
1.5 GATA4 contributes to modification of cytoskeleton architecture and cell
adhesions
To validate differentially expressed genes in the mRNA microarray, we assayed EMT-
associated genes with RT-qPCR in two HB cell lines. Additionally, we evaluated 
expression of E-cadherin (CDH1), N-cadherin (CDH2), proto-oncogene c-Src (SRC),
matrix metalloproteinase 1 (MMP1), and tissue inhibitor of metalloproteinases 2
(TIMP2) which were not initially noted in the microarray but are hallmarks of EMT
(164–166). Seven of the studied genes were associated with cell motility or cytoskeleton 
rearrangements, two were related to apico-basal polarity and cell adhesions, and four 
genes were connected to remodeling of extracellular matrix. In HUH6 cells gene 
expression was changed to same direction than it was observed in array, but all the 
results were not consistent with HepG2 HB cell line (Table 6). The HepG2 cell line was 
originally derived from an older (15 years) HB patient compared to HUH6 cells 
representing HB in infant. HB pathogenesis is likely partially different in older HB 
Figure 12. Enriched biological processes in microarray data of GATA4 silenced HUH6 
cells. Biological processes relating to ontogenesis, wound healing, cell polarity, and response 




patients, but it has not been widely studied if there is for example higher mutation burden 
in this group compared to younger HB patients. In sum, GATA4 seems to regulate 
multiple genes involved EMT-related processes, but exact mechanism may be
environment dependent. To elucidate whether all or some of the genes studied here are 
under direct transcriptional control of GATA4 in HB cells, chromatin-
immunoprecipitation assay (167) should be utilized in the future studies.











ADD3 0.73 1.50 cell motility and cytoskeleton rearrangements (168)
AHNAK 0.61 0.72 cell motility and cytoskeleton rearrangements (169)
CDH1 1.47 2.20 cell-to-cell adhesions and apico-basal polarity (170)
CDH2 0.71 1.39 cell-to-cell adhesions and apico-basal polarity (171)
COL4A1 1.46 ns extracellular matrix remodeling (172)
DOCK8 0.71 ns cell motility and cytoskeleton rearrangements (173)
IGFBP1 0.51 0.70 extracellular matrix remodeling (174)
MSF 0.57 ns extracellular matrix remodeling (175)
MMP1 0.46 2.37 extracellular matrix remodeling (166)
RHOB 1.46 1.55 cell motility and cytoskeleton rearrangements (176)
RHOU 0.69 ns cell motility and cytoskeleton rearrangements (177)
SRC 0.77 1.26 cell motility and cytoskeleton rearrangements (165)
SYTL2 0.48 ns cell motility and cytoskeleton rearrangements (178)
*=p-value < 0.05. ns=not significantly differentially expressed. 
Cadherin-switch is an EMT-related process wherein E-cadherin is downregulated and 
N-cadherin is upregulated enabling changes in cell polarity (179). A prior study in 
canine kidney cells showed that CDH1 is directly upregulated by GATA4 (170). We 
observed reversed cadherin-switch after GATA4 silencing both in our gene expression 
analysis and immunofluorescence staining (Table 6, Figure 13C-F). A shift towards E-
cadherin dominancy supports epithelial and less-motile phenotype. Knockdown of 
GATA4 also reduced actin polymerization and stress fiber accumulation in HUH6 cells 
(Figure 13A-B) suggesting that GATA4 is involved in both the regulation of cell





1.6 GATA4 silencing reduces cell migration 
Rearrangement of adhesion and cytoskeletal proteins is a prerequisite for cell migration 
and invasion (180). We found that cells with undisturbed GATA4 expression were 
remarkably more mobile (Figure 14A-B, E) than those treated with GATA4 siRNA 
(Figure 14C-E). Similar findings were presented in study by Pei et al., who showed that 
upregulated GATA4 increased migration and invasion in HUH6 HB cells by regulating 
expression of microRNA-125b (miR125b) and DKK3 (158). However, our microarray 
analysis did not detect alteration in DKK3 expression after GATA4 silencing in the same 
cell line. Microarrays have been criticized for inaccuracies (181) which may explain this 
discrepancy, but further studies are needed to conclude significance of GATA4-DKK3 
axis. Small non-coding RNAs were not included in the microarray used.  
 
 
Figure 13. Immunofluorescence staining of 
EMT markers. Stress fibers (arrowhead) 
accumulated in HUH6 cells with intact 
GATA4 expression (A). After GATA4 
silencing, membranous actin (arrow) was 
more prominent (B). F-actin was stained with 
phalloidin (A, B). GATA4 knockdown 
upregulated E-cadherin expression in HUH6 
cell membranes (arrowhead) (C-D). N-
cadherin was predominant in membranes 
(arrowhead) of cells treated with NT siRNA 
(E-F). Scale bar 50 μm (A-G). NT=non-
















1.7 Overexpression of GATA4 in primary hepatocytes 
Since we observed that GATA4 silencing modifies EMT-related gene expression, we 
next explored whether GATA4 overexpression shifts normal hepatocytes towards a 
malignant phenotype. To test this, GATA4 expression was enforced in human primary 
hepatocytes (PH) from adult donor. Low baseline expression of GATA4 was detected 
in PH (HUH6/PH GATA4 mRNA ratio 0.23, p-value 0.002). Following plasmid 
transfection, GATA4 expression increased 229-fold. Utilizing RT-qPCR, we 
investigated expression of EMT-related genes after enforced GATA4 upregulation. 
Most of these genes (10/14) were significantly altered (Figure 15A-C). Furthermore, 
8/10 were changed to opposite direction than in GATA4 silenced HUH6 cells suggesting 
that GATA4 is able to modify gene expression of differentiated hepatocyte towards 
mesenchymal cell type. It is noteworthy that the baseline of GATA4 mRNA expression 
was approximately four times higher in HUH6 cells compared to PH. Enforced 
overexpression resulted remarkably higher GATA4 mRNA expression in PH than the 
aforementioned baseline. Actions of GATA4 may differ dose-dependent manner and 
this should be noted when evaluating these results.  
 
 
Figure 14. Motility of HUH6 cells after GATA4 silencing. Migration pace was 2.6-fold (E) 
higher in cells with undisturbed GATA4 expression (A-B) compared to GATA4 knockdown cells 
(C-D) at 24 h timepoint. Black line demonstrates the cell front (A-D). Mean of three experiments 
± SD is shown in bar plot (E). *p-value<0.05. NT=non-targeting. G4=GATA4. 
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Altered GATA4 expression has also been demonstrated in the adult form of HCC, but 
interestingly it has been suggested to have tumor suppressor role in this cancer type 
(182). Of note, the etiology of adult HCC differs from HB, as HCC often manifests in
inflamed or injured liver. This observation underlines the idea that GATA4 actions in 
liver might be dependent on other molecular events, such as inflammation or 
ontogenesis, occurring simultaneously with tumorigenesis. 
1.8 Summary of the findings related to GATA4 in HB
Transcription factor GATA4 is highly expressed in HBs and this is especially evident in 
tumors with embryonal histology. Additionally, excessive GATA4 expression was
observed in HB cell lines. Using RNA interference based methodology, GATA4 was
silenced and its impact on global transcriptome was assessed. We noted that high 
proportion of altereted genes were associated with EMT-related processes. Further, we
observed that the phenotype of GATA4 silenced HB cells shifted towards epithelial and 
immobile cell as the E/N-cadherin ratio turned around and number or migratory cells 
decreased. Enforced GATA4 expression in primary hepatocytes was able to modify gene 
expression towards that of characteristic for HB. Taken together, GATA4 associates 
with mesenchymal-like phenotype in HUH6 cells and its silencing leads to reduction of 
malignant behaviour of HB cells. It has to be noted, however, that all the
experimentations were conducted in simple cell models and actions of GATA4 might 
be different in a complex tumor environment in vivo.
Figure 15. Gene expression changes in primary hepatocytes after enforced GATA4 
expression. Five genes (5/7) associated with cell motility and cytoskeleton rearrangements were 
upregulated after transfection with GATA4 expression plasmid (A). GATA4 upregulated both 
CDH1 as well CDH2 expression in primary hepatocytes (B). Three genes (3/4) linked to 
extracellular matrix remodeling were altered by upregulated GATA4. Experiment was 
performed in triplicate and bar plots indicate relative mean ±SD. *=p-value<0.05. **p-
value<0.01. G4=GATA4 expression plasmid. Ctrl=control plasmid.
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2 Neuropilin expression in hepatoblastoma HB (II)
2.1 Neuropilin-2 expression in HB patient samples and cell lines
Neuropilins (NRP1 and NRP2) are non-tyrosine kinase receptors with plethora of 
ligands  expressed both in physiological as well pathological situations (183–185). In 
cancer cells, upregulation of NRPs has been associated with several pro-malignant
processes including chemoresistance, increased viability, and metastatic behavior 
(99,186,187). Moreover, recent studies have demonstrated that NRP1 and NRP2 may 
serve as diagnostic and prognostic markers in liver carcinoma (98,188).
To investigate the expression of NRPs in HB, we measured mRNA and protein levels 
in patient samples and HB cell lines. Consistent with prior studies (80,189), we did not 
observe considerable NRP1 or NRP2 expression in normal hepatocytes, whereas LSECs 
expressed both NRPs, providing an internal control (Figure 16A-B). All of HB patient 
samples (n=20) demonstrated NRP1 immunoreactivity, half of HBs (50 %) had low or 
intermediate expression (Figure 16C) and rest of the samples (50 %) showed high 
expression (Figure 16E). NRP2 was expressed in 95 % of HBs, 55 % of the samples 
had low or intermediate expression (Figure 16D) and 40 % of the samples had high 
NRP2 immunoreactivity (Figure 16F), respectively. One HB patient sample was NRP2 
negative.   
Patients included in this study formed subgroups of 2-8 subject in each based on major 
clinical variables such as staging, metastasis, and survival. This kind of data is extremely 
vulnerable to bias owing to the small sample size. For this reason, we opted not to 





We also evaluated NRP1 and NRP2 expression in 6 HB cell lines. Primary hepatocytes 
were used as a control to detect baseline expression. At the mRNA level, significantly 
upregulated NRP1 was detected in 4 of 6 six HB cell lines (Figure 17A) and similar 
expression was evident at protein level (Figure 17B). All HB cell lines demonstrated 
overexpression of NRP2 at the mRNA level (Figure 17C). High NRP2 protein 
expression was observed in 5/6 HB cell lines, whereas one cell line had negligible 
expression like primary hepatocytes (Figure 17D).  
Figure 16. NRP1 and NRP2 
expression in normal liver and HB 
patient samples. Normal hepatocytes 
did not show considerable NRP1 or 
NRP2 expression whereas LSECs 
(arrow) were positive for both markers 
(A-B).  NRP1 expression, 10/20 with 
low/intermediate intensity (C) and 10/20 
with high intensity (E),  localized to 
cytoplasm and membranes of HB cells. 
Intermediate/low NRP2 expression (D) 
was detected in 11/20 HBs and 8/20 HBs 
had high expression (F). NRP2 
expression was detected predominantly 
in cytoplasm with lesser amounts in 
membranes (D, F). Scale bar = 20 μm. 
LSEC=liver sinusoidal endothelial cell.  
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Interestingly, in the study by Wittman et al. NRP2 expression was linked to 
mesenchymal and dedifferentiated phenotypes in HCC (189). We observed abundant 
NRP2 expression in majority of HB patient samples and cell lines suggesting that NRP2 
expression might be a common feature of poorly differentiated hepatic malignancies.
2.2 Knockdown of NRP2 in HUH6 cells and its effect on cell viability
As NRP2 expression was consistently higher than NRP1 expression (1400- to 4300-fold 
vs. 70- to 700-fold ratio) in our HB cell models, we decided to focus on the role of NRP2 
in HB pathobiology. We silenced NRP2 expression in HUH6 cells and evaluated 
resultant changes in cell morphology and behavior. Utilizing siRNA transfections, we 
achieved approximately 70-80 % reduction in NRP2 expression (Figure 18A-C). Since 
the baseline expression of NRP2 was basically non-existent in primary hepatocytes, this 
remaining 20-30 % expression in HUH6 cells may still have a significant role in 
malignant processes. To overcome this, CRISPR-Cas9 genome editing technology 
(190), which enables complete inactivation of the gene, could be utilized in the future 
studies. 
Figure 17. NRP1 and NRP2 mRNA and protein expression in HB cell lines. Mean of NRP1 
and NRP2 mRNA counts (±SD) measured with RNA sequencing (A, C) and protein expression (B, 
D) in HB cell lines and primary hepatocytes. Protein band intensities are normalized to total 
protein expression of the corresponding lane and relative band intensity describes expression in 
relation to primary hepatocytes (B, D). #=adjusted p-value<0.05. PH=primary hepatocyte.
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Aberrant NRP2 signaling has been associated with increased cell survival in variety of 
solid tumor models including breast, gastric, and cervical cancer cell lines (191–193).
To investigate whether NRP2 affects also on HB cell viability, we assessed activity of 
mitochondrial dehydrogenases (WST-1) and ATP production. As with aforementioned 
cancer cell models, downregulation of NRP2 decreased HUH6 cell viability 
approximately 30% compared to cells with intact NRP2 expression (Figure 18C-D). In 
addition to other pro-survival effects, NRP2 overexpression was recently linked to 
cisplatin resistance in neuroblastoma cells (194). As cisplatin is a mainstay of HB 
chemotherapy, NRP2 targeting may also increase HB cell chemosensitivity. 
2.3 Cytoskeleton remodeling and migration after NRP2 silencing
NRP2 expression has been linked to stem-cell renewal and increased tumor cell motility 
in other pediatric and gastrointestinal cancers (189,192,195,196). To investigate if NRP2 
contributes to similar processes in HB, we explored stress fiber formation and migration 
in HUH6 cells after NRP2 knockdown. Re-organization of actin cytoskeleton is a 
prerequisite for tumor cell motility and subsequent metastasis [reviewed in (197)]. An
essential part of this remodeling process is polymerization of actin fibers resulting in 
structures called stress fibers. These stress fibers further organize to form membrane 
protrusions that enable cell movements. 
We noted a drastic decrease in actin stress fibers after NRP2 silencing (Figure 19D-F)
compared to cells with undisturbed NRP2 expression (Figure 19A-C). Membrane
Figure 18. NRP2 silencing 
efficacy and impact on HUH6 cell 
viability. NRP2 expression 
decreased 70-80 % at mRNA (A) 
and protein (B) level. Band intensity 
was normalized to total protein 
expression of the corresponding 
lane utilizing stain-free technology 
(B). Cell viability measured with 
WST-1 (C) and ATP assays (D) 
after NRP2 knockdown. Bar plots 
are represented as a mean ± RSD of 
three independent experiments.  
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protrusions were more prominent in HUH6 cells with intact NRP2 expression (Figure 






Since NRP2 expression in HB cells was associated with morphology promoting motility, 
we next assayed whether this correlates with actual migration rate. Using transwell 
assays, we noted that NRP2 silencing (Figure 20B) led to a significant decrease in the 
number of migrated cells (Figure 20C) compared to HUH6 cells treated with NT control 
siRNA (Figure 20A). Considering the importance of cytoskeleton re-organization and 
motility for subsequent metastasis, targeting proteins crucial for these processes has 
potential in management of cancer. Antibodies blocking NRP2 activity have been 
investigated in pre-clinical cancer models with promising results (192,198). As current 
pharmaceutical treatment for HB is based on traditional chemotherapy associated with 
toxic side effects, targeted therapies such as anti-NRP2 antibodies may offer an 
additional novel tool to tackle these tumors.  
 
 
Figure 19. F-actin staining in HUH6 cells with undisturbed or silenced NRP2 expression. 
The white arrow indicates actin membrane protrusions in NT siRNA (A) and NRP2 siRNA 
treated HUH6 cells. Close-up of stress fibers (white arrowhead) (B-E). DAPI nuclear 








2.4 Summary of the findings related to NRP2 in HB 
Both NRP1 and NRP2 are overexpressed in majority of HB patient samples and cell 
lines. RNA interference mediated silencing of NRP2 attenuated HUH6 cell survival. 
Further, depolymerization of actin fibers was observed in NRP2 knockdown cells 
suggesting impaired mobility. This was confirmed with migration assay demonstrating 















Figure 20. Effect of NRP2 expression on cell motility in HUH6 cells. NRP2 silencing reduced 
cell motility (B) compared to cells treated with NT control siRNA (A). A 55 % decrease in the 
number of migrated cells were observed (C). Bar plot represents the mean of three independent 
experiment ± RSD. **p-value<0.01. NT=non-targeting.  
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3 Pre-clinical evaluation of chloroquine in HB treatment (III)
3.1 HB cell viability after chloroquine treatment 
Chloroquine is known to be a potent autophagy inhibitor. This is one of the principal
mechanisms thought to underlie its efficacy in cancer treatment. Increased autophagy 
flux has been associated with multiple pro-tumorigenic processes such as altered DNA-
damage repair and metabolomic reprogramming (199,200). In HB increased autophagic 
activity has been linked to tumor development in mice models (201). Based on that 
observation, we hypothesized that interventions targeting autophagy flux could be 
beneficial in HB management. 
We established seven HB spheroid models (six PDX-derived cell lines and HUH6) and 
treated each with increasing concentrations of CQ (1 μM, 5 μM, and 10 μM). 
Remarkable changes in spheroid morphology indicative of decreased cell viability were
observed in both a dose- and time-dependent manner (Figure 21A-G). Solid tumors 
typically contain differentially oxygenated and nourished areas. This phenomenon is 
recapitulated in spheroids - the outmost cells are typically proliferating, cells in the 
middle are quiescent, and interior cells are necrotic due to oxygen and nutrient 
deprivation (Figure 21H). This capability to mimick tumor architechture is a great 
advantage compared to traditional 2D monolayer cultures, though organoids would be 









Figure 21. HB spheroid morphology after 48 h and 96 h of CQ treatment. Light areas 
indicative of proliferating cells decreased in a time- and dose dependent manner in seven 
HB spheroid models (A-G). Representation of different zones in spheroid (H).  
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To quantify the effect of CQ on HB cell viability, we measured ATP concentration and 
activation of apoptosis effector proteins caspase 3 and 7 after 48 h and 96 h of CQ 
treatment. At the 48 h timepoint, two out of seven models demonstrated decrease in ATP 
concentration and all the models exhibited increased apoptosis with 10 μM CQ 
concentration (Figure 22A-G). By 96 h, 6 of 7 HB spheroid models demonstrated 
significantly decreased viability (Figure 22A-E, H). Caspase 3/7 activation was even 
more pronounced in 4 of 7 models after 96 h of CQ treatment (Figure 22A-C, E). 
Consistent with our findings, CQ has demonstrated pro-apoptotic and anti-proliferative 
actions in various other cancer models (111,112,202).
Figure 22. Effect of CQ administration on HB spheroid viability and caspase 3/7 activation
at 48 h and 96 h after treatment initiation (A-G). *p-value < 0.05. **p-value < 0.01. CQ 
concentrations: 0 μM, 1 μM, 5 μM, and 10 μM. 
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One major limitation of spheroid cultures is low cell density. Most high throughput 
applications require higher cell counts. Therefore, we validated spheroid findings in 2D 
cell cultures. We treated HB cell monolayers with fixed concentrations of CQ and 
measured clone formation potential after 4 d and 14 d of treatment. CQ (5-10 μM) had
a statistically significant effect on clonogenic potential formation at both timepoints 
(Figure 23A-C).
3.2 Metabolomic profile of chloroquine treated HUH6 cells
Disturbed autophagic flux has been associated with decreased nutrient availability in 
cancer cells [reviewed in (203)]. We investigated the effect of CQ (5 μM) on 100 key 
metabolite concentrations in HUH6 cell line, using a liquid chromatography-mass 
spectrophotometry based method. This profiling identified 12 significantly decreased 
metabolites and 4 significantly increase metabolites in CQ treated cells compared to the 
control (Table 7). 
Figure 23. Clonogenic potential in HUH6 2D cell cultures treated with CQ. After 4 days of 
treatment, the number of colonies decreased significantly with all the doses tested (A, C). 
Similarly, 5 μM and 10 μM doses reduced number of colonies after 14 d of treatment (B, C).  CQ 
concentrations: 0 μM, 1 μM, 5 μM, and 10 μM.
55 
 


















Metabolite enrichment analysis highlighted malate-aspartate shuttle to be most 
abundantly altered pathway (>12-fold increase; Figure 24A). Aspartate was also 
denoted to be significantly changed in single metabolite analysis; a 75 % reduction in
aspartate concentration was observed in CQ treated vs. control cells (Figure 24B). 
Interestingly, aspartate supplementation was able to rescue HUH6 cells from CQ 
induced cell death (Figure 24C) suggesting that aspartate availability limits HB cell 
survival. A similar effect on aspartate availability was demonstrated in pancreatic cancer 
cells treated with CQ (110), suggesting that aspartate biosynthesis may be crucial target 
of this drug in cancer cells. 
The most significantly altered single metabolite was nicotine adenine dinucleotide 
(NAD+) which was reduced 60 % after CQ treatment compared to cells receiving control 
treatment (Figure 24D). Furthermore, a substantially higher proportion of the NAD pool 
was in the hydrogenated NADH form in CQ treated cells (Figure 24E), suggesting that 
CQ impacts the regulation of NAD redox balance. NAD+  has an important role in variety 
of cellular processes such as DNA-damage response, biosynthesis, and energy 
metabolism  [reviewed in (204)]. Altered NAD+ synthesis has been studied as a 










3.3 Cell death associated gene expression changes after chloroquine treatment 
To elucidate molecular mechanisms by which CQ triggers cell death in HB cells, we 
performed Cell Death Pathway RT-qPCR array. This array detected 16/84 differentially 
expressed genes (Table 8) in HUH6 cells treated with 5 μM CQ for 96 h: 6 genes were 
associated with apoptosis (CD40LG, CD40, TNF, TP53, IFNG, and ABL1), 5 genes 
related to autophagy (ESR1, IGF1, SQSTM1, BECN1, and CTSS), and 5 classified as 







Figure 24. Enriched metabolites in HUH6 cells treated with 5 μM of CQ. Metabolite 
enrichment analysis demonstrated significant over representation of malate-asparte shuttle 
related metabolism (A). Aspartate concentration decreased 75 % after CQ treatment (B). 
Aspartate supplementation rescued HUH6 cells from CQ triggered decrease in viability (C). 
Asparate did not show independent effect on viability (C). NAD+ concentration decreased 60 % 
in CQ treated cells versus control treatment (D). CQ shifted NAD+/NADH balance towards 
reduced form (E). Bar plots are presented as relative values of mean ± RSD *=p-value<0.05. 
**p-value<0.01. CQ=chloroquine. ASP=aspartate (10 mM).  
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Table 8. Altered death signaling associated genes after CQ treatment.

















3.4 CQ attenuates PARP expression in HB cells
Considering that we observed decreased NAD+ concentrations in our metabolomic 
profiling and the fact that action of poly(ADP)-ribose polymerase (PARP) is dependent 
on NAD+ availability (207), PARP was chosen for further analysis. PARP1 and PARP2 
protein expression was evaluated in three HB cell lines treated with 5 μM of CQ utilizing 
western blotting. By this method, we observed statistically significantly reduced PARP1 
expression in 2/3 cell lines (Figure 25A) whereas PARP2 expression decreased in one 
of studied models (Figure 25B). Furthermore, we performed immunofluorescence 
staining to validate localization of PARP1 in HUH6 cells. After 96 h CQ treatment, 
nuclear PARP1 expression decreases remarkably (Figure 25C). Taken together, NAD+
depletion mediated PARP inhibition seems to be one of the mechanisms of action for 









PARPs are involved in various processes in cancer cells including epigenetic 
modification, DNA-damage response, and signal transduction [reviewed in (208)]. 
Small molecule PARP inhibitors have been utilized in treatment of several cancers 
including ovarian cancer and breast cancer (209,210). Interestingly, abundant activation 
Figure 25. PARP expression in HB cells after treatment with 5 μM CQ. Statistically 
significant decrease in PARP1  expression is evident in 2/3 HB cell lines (A). PARP2 
expression is reduced significantly in 1/3 HB cell lines (B). Bar plots are represented as a 
mean of three experiment ±RSD. Band intensity is normalized to total protein expression of 
corresponding lane. PARP1 is expressed mainly in nuclei of HUH6 cells (C-E). Drastic 
decrease in PARP1 positive nuclei is observed after CQ treatment (F-H).  
59 
 
of PARP1 has been reported in HB cells and it is associated with modification of 
aberrantly expressed tumor suppressor genes (211). Moreover, it has been suggested that 
CQ may potentiate the effect of PARP inhibitors; for example, this has been 
demonstrated in HCC treated with nirabarib and CQ (212). In sum, abundant PARP 
expression has been shown to be important for hepatocellular malignant behavior and 
CQ attenuates PARP expression proposing that CQ could be beneficial in management 
of aggressive HB either as a monotherapy or combined with other agents. 
3.5 Summary of the findings related to CQ treatment in HB
We observed markedly decreased cell viability and increased apoptosis in seven HB 
spheroid model treated with CQ (1 μM, 5 μM, or 10 μM). These effects were both time-
and dose-dependent in most of the models. Similarly, cell viability was decreased in 2D 
cell cultures treated with fixed doses of CQ. Metabolomic profiling demonstrated altered
aspartate and NAD+ metabolism after CQ treatment. Aspartate supplementation was 
able to rescue HB cells from CQ induced cell death suggesting that cancer cells sensitive 
to aspartate depletion are potential targets of CQ treatment. We also observed reduced 
PARP1/2 mRNA and protein expression in HB cells treated with CQ. As PARP function 
is NAD+-dependent, metabolic changes caused by CQ administration may inhibit 
PARPs, indicating that CQ also has potential in treatment of cancers sensitive to PARP 
inhibitors. A schematic view of the proposed mechanisms of action is shown in Figure 
26.
Figure 26. Proposed mechanisms of CQ treatment in HB cells. 
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CONCLUSIONS AND FUTURE DIRECTIONS  
 
This study elucidated molecular mechanisms involved in HB pathogenesis including 
aberrant gene expression and metabolic vulnerabilities (summarized in Figure 27). We 
identified potential targets for novel therapeutic approaches in HB and introduced new 









Aim-by-aim conclusions and future directions: 
1. Transcription factor GATA4 is crucial for the early stages of normal liver 
development [reviewed in (21)]. Our study demonstrated high GATA4 in majority of 
HB patient samples and PDX-derived cell lines, underscoring the notion that HB cells 
arise from the early hepatic progenitor cells. In vitro, GATA4 silencing changed the 
expression of EMT-associated genes suggesting that GATA4 maintains similar 
Figure 27. Summary of the observations described in this thesis. High GATA4 expression 
was detected in HBs and was associated with upregulation of EMT-related genes and increased 
motility (I). Abundant NRP2 expression was noted in HB patient samples and cell lines (II) and 
was linked to cell survival and migration which may be attenuated with anti-NRP mAb. CQ 
decreased aspartate (Asp) and NAD+ concentration in HB cells (III). Moreover, decreased 
PARP expression was observed after CQ administration. We suggest that these mechanisms 
reduce nucleotide biosynthesis and DNA-damage repair response leading to cell death. Figure 
was created with BioRender.com. 
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processes in HB than its physiological tasks are during the development. Furthermore, 
silenced GATA4 expression led to altereted cell junction dynamics and cytoskeleton 
structure in HB cells linking GATA4 with the mesenchymal phenotype in HB. 
In future studies, the findings described herein should be assessed in animal models or 
organoids to confirm the role of GATA4 in HB pathogenesis. 
2. NRPs are multifunctional non-tyrosine kinase receptors involved in pathogenesis of 
multiple cancers [reviewed in (213)]. Monoclonal antibodies targeting NRP2 have been 
developed as potential therapies (192). We observed that NRP1 and NRP2 are highly
expressed in HBs whereas normal hepatocytes do not display these markers, indicating 
that NRP expression is a tumor-specific feature. NRP2 silencing decreased cell survival 
and motility suggesting that therapeutic interventions targeting NRP2 may have
potential in the management of aggressive HB. 
In our study, the number of patient samples was limited, and our observations need to
be confirmed in a larger sample set. Moreover, the correlation between NRP expression 
and clinical variables should be evaluated to assess the potential of NRPs as prognostic
biomarkers in HB. Additionally, the efficacy of anti-NRP2 monoclonal antibodies
should be investigated in future in vitro and in vivo studies to assess their potential in 
HB treatment. 
3.  Several clinical trials studying the potential of CQ in the treatment of advanced cancer
are ongoing or completed [reviewed in (214)]. We noted a time- and dose-dependent 
effect of CQ on cell viability and apoptosis rate in our 3D HB cell models suggesting
that CQ has anti-tumorigenic potential in HB. Furthermore, CQ treatment led to a
reduction of aspartate concentration, and CQ triggered cell death was rescued with 
aspartate supplementation suggesting that HB cells are dependent on aspartate 
availability. NAD+/NADH balance shifted towards NADH after CQ treatment. We
propose that this reduction in NAD+ availability impairs PARP expression and function
as we observed decrease in PARP1 and PARP2 expression at mRNA and protein level 
96 h post-treatment. 
As a next step, CQ efficacy should be studied in mice models as a monotherapy or
combined with the traditional HB chemotherapeutics cisplatin and doxorubicin. In the 
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